Nuvalent to Participate in the Cantor Global Healthcare Conference 2025

Core Insights - Nuvalent, Inc. is a clinical-stage biopharmaceutical company focused on developing targeted therapies for cancer, specifically for clinically proven kinase targets [3] - The company will participate in the Cantor Global Healthcare Conference 2025, with CEO James Porter and CFO Alexandra Balcom scheduled for a fireside chat on September 4, 2025 [1] Company Overview - Nuvalent specializes in creating precisely targeted therapies aimed at overcoming the limitations of existing cancer treatments [3] - The company utilizes expertise in chemistry and structure-based drug design to develop innovative small molecules that can address issues such as resistance, adverse events, and brain metastases [3] - Nuvalent is advancing a pipeline that includes investigational candidates for ROS1-positive, ALK-positive, and HER2-altered non-small cell lung cancer, along with multiple discovery-stage research programs [3]